Compugen (CGEN) Adds Two Potential Therapeutic Proteins To Its Research Pipeline 
10/19/2005 5:11:38 PM

Speaking today at the BIO 2004 Annual International Convention, Martin Gerstel, Chairman of Compugen Ltd. (Nasdaq:CGEN), disclosed two novel potential therapeutic proteins which Compugen has recently added to its research pipeline: CGEN M-3, a soluble kinase receptor with potential applications in various types of cancer, and CGEN P-4, a peptide with potential applications in obesity and various eating disorders.